Orchestra BioMed Holdings Inc. (OBIO)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $570.61M
Last updated: Nov 17, 2026 at 11:05 AM ET
Orchestra BioMed Holdings Inc. (OBIO) Competitors
The companies most similar to Orchestra BioMed Holdings are Climb Bio (CLYM), Solid Biosciences LLC (SLDB) and Entera Bio (ENTX). By market cap, Orchestra BioMed Holdings ranks 7th of the 13 companies on this page; Oric Pharmaceuticals (ORIC) is the largest at $814.71M.
Peer Comparison
OBIO's ROIC of -97.0% is below the peer median of -8.5%, and its revenue growth of -89.4% is below the median of 0.0%. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Orchestra BioMed Holdings (OBIO) | $570.61M | N/A | 14.7x | -182.5% | -97.0% | -89.4% | 0.00% |
| Climb Bio Inc (CLYM) | $608.53M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Solid Biosciences LLC (SLDB) | $763.42M | N/A | N/A | 0.0% | N/A | -100.0% | 0.00% |
| Entera Bio Ltd (ENTX) | $541.57M | N/A | N/A | 0.0% | -8.5% | -100.0% | 0.00% |
| CorMedix Inc (CRMD) | $370.64M | 6.3x | 0.9x | 15.5% | 13.9% | -47.7% | 0.00% |
| Tevogen Bio Holdings Inc. (TVGN) | $406.59M | N/A | N/A | 0.0% | 2022.8% | 0.0% | 0.00% |
| Sana Biotechnology Inc (SANA) | $605.26M | N/A | N/A | 0.0% | -46.8% | 0.0% | 0.00% |
| DiaMedica Therapeutics Inc (DMAC) | $474.29M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Ovid Therapeutics Inc (OVID) | $479.38M | N/A | 335.8x | 0.0% | N/A | -88.3% | 0.00% |
| Phathom Pharmaceuticals Inc (PHAT) | $492.63M | N/A | 1.8x | -30.2% | 11.4% | 71.1% | 0.00% |
| Immix Biopharma Inc (IMMX) | $657.09M | N/A | N/A | 0.0% | -14.9% | 0.0% | 0.00% |
| Oric Pharmaceuticals Inc (ORIC) | $814.71M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Olema Pharmaceuticals Inc (OLMA) | $662.30M | N/A | N/A | 0.0% | -53.8% | 0.0% | 0.00% |
| Peer median | $573.42M | 6.3x | 1.8x | 0.0% | -8.5% | 0.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to Orchestra BioMed Holdings, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Climb Bio Inc (CLYM) | Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases. | CLYM competitors |
| Solid Biosciences LLC (SLDB) | Solid Biosciences Inc., a life sciences company, is dedicated to developing therapies for Duchenne muscular dystrophy (DMD) in the United States. | SLDB competitors |
| Entera Bio Ltd (ENTX) | Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally administered large molecule therapies... | ENTX competitors |
| CorMedix Inc (CRMD) | CorMedix Inc., a biopharmaceutical company, focuses on developing and marketing therapeutic products for the prevention and treatment of infectious... | CRMD competitors |
| Tevogen Bio Holdings Inc. (TVGN) | Tevogen Bio Holdings Inc. is a clinical-stage biotechnology company that develops off-the-shelf precision T cell therapeutics in virology, oncology... | TVGN competitors |
| Sana Biotechnology Inc (SANA) | Sana Biotechnology, Inc., a biotechnology company, focuses on the use of modified cells as medicines. The company is headquartered in Seattle, Washington. | SANA competitors |
| DiaMedica Therapeutics Inc (DMAC) | DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company, develops treatments for neurological and kidney diseases. | DMAC competitors |
| Ovid Therapeutics Inc (OVID) | Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medications for patients and families with neurological disorders in the United States. | OVID competitors |
| Phathom Pharmaceuticals Inc (PHAT) | Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. | PHAT competitors |
| Immix Biopharma Inc (IMMX) | Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, is dedicated to the development of various tissue-specific therapies in oncology... | IMMX competitors |
| Oric Pharmaceuticals Inc (ORIC) | ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of cancers. | ORIC competitors |
| Olema Pharmaceuticals Inc (OLMA) | Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development... | OLMA competitors |
Frequently Asked Questions About OBIO
Who are Orchestra BioMed Holdings' main competitors?
The companies most similar to Orchestra BioMed Holdings include Climb Bio (CLYM), Solid Biosciences LLC (SLDB), Entera Bio (ENTX), CorMedix (CRMD) and Tevogen Bio Holdings (TVGN), listed from the closest match.
Who is Orchestra BioMed Holdings' biggest competitor?
Oric Pharmaceuticals (ORIC) is the largest of the similar companies at $814.71M; Climb Bio (CLYM) is the closest match by business profile, size, sector and industry.
How does OBIO stock compare with its competitors?
OBIO's P/S is 14.7x against a peer median of 1.8x; its net margin is -182.5% against a peer median of 0.0%.
Which of Orchestra BioMed Holdings' competitors pays a higher dividend?
Orchestra BioMed Holdings pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Orchestra BioMed Holdings bigger than its competitors?
No. Orchestra BioMed Holdings is 7th by market cap among the 13 companies on this page; the largest is Oric Pharmaceuticals (ORIC) at $814.71M.
OBIO pages: Overview, Earnings, Forecast, Financials, Competitors